Introduction
T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10-15% and 25% of pediatric and adult ALL, respectively. Although the prognosis of T-ALL has improved in recent years, especially in children, the outcome of relapsed and chemoresistant T-ALL remains dismally poor.
1,2 Thus, major efforts are being made to develop targeted molecules against deregulated signaling pathways that sustain T-ALL cell growth and survival. [3] [4] [5] The mammalian target of rapamycin (mTOR) serine/threonine kinase belongs to two separate multi-protein complexes, referred to as mTORC1 and mTORC2. 6 The mTORC1 complex, which is inhibited by rapamycin/rapalogs, controls mRNA translation through the phosphorylation of the translation repressor 4E-BP1, 7 whereas mTORC2 is involved in regulating proliferation and survival through phosphorylation of Akt on Ser 473.
8 mTORC2 is usually considered to be rapamycin resistant. 9 Both mTORC1 and mTORC2 are activated in most of T-ALL patients underscoring these complexes as major targets for T-ALL treatment. 10 mTORC1/mTORC2 activation in T-ALL usually depends on upregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt axis, which is a common event in T-ALL patients 11 and has a negative impact on prognosis. 12, 13 There is a strong rationale for targeting PI3K/Akt/mTOR signals in T-ALL, as in mice hematopoietic stem cells, PTEN deletion (which results in PI3K/Akt/mTOR hyperactivation) led to a T-ALL. 14, 15 Moreover, recent findings in a zebrafish model, have highlighted that the transition from T-lymphoblastic lymphoma to T-ALL was characterized by increased phosphorylation levels of Akt. 16 The allosteric inhibition of mTORC1 by rapamycin has only modest effects on T-ALL cells. 17 This could be because, among other things, of the fact that rapamycin is mainly cytostatic and does not dephosphorylate the translational repressor 4E-BP1 in preclinical models of T-ALL. 18 Recently, however, ATP-competitive inhibitors specific for the mTOR kinase active site have been developed. These compounds target both mTORC1 and mTORC2 and are more active than rapamycin/rapalogs at least in terms of inhibiting the phosphorylation of p-4E-BP1. 19 In the following study, we have explored the therapeutic potential of three active-site mTOR inhibitors, PP-242, OSI-027 and AZD-8055 against both T-ALL cell lines and primary samples from T-ALL patients displaying activation of mTORC1 and mTORC2. The inhibitors affected T-ALL cell line viability as documented by MTT assays. The drugs affected to a much lower extent the proliferation of peripheral blood T-lymphocytes from healthy donors stimulated with phytohemagglutinin (PHA-M) and interleukin-2 (IL-2). Unlikely rapamycin, we found a marked inhibition of mRNA translation in T-ALL cell lines treated with active-site mTOR inhibitors. Remarkably, PP-242 and OSI-027 targeted a CD34 þ /CD7 À /CD4 À lymphoblast subset in T-ALL patients, which may correspond to leukemia-initiating cells (LIC) 20 and decreased dexamethasone resistance in this sub-population.
In conclusion, the inhibitors displayed a remarkable antileukemic activity through inhibition of mTORC1 and mTORC2 activity. The lower cytotoxicity against healthy T-lymphocytes ex-vivo suggests a favorable therapeutic index, which emphasizes the development of active-site mTOR inhibitors as clinical candidates for therapy in T-ALL.
Materials and methods

Materials
PP-242, rapamycin, vincristine (VCR), and AMD3100 were purchased from Sigma-Aldrich (St Louis, MO, USA). PI-103 was from Alexis Biochemicals (San Diego, CA, USA). OSI-027, AZD-8055 and ABT-263 were bought from JS Research Chemicals Trading (Wedel, Germany). The PIM-1 kinase inhibitor (3-Cyano-4-phenyl-6-(3-bromo-6-hydroxy)phenyl-2(1H)-pyridone 21 ) was from Tocris Bioscience (Bristol, UK). ON-TARGET plus SMART pool small interfering RNAs (siRNAs) targeting human hypoxia-inducible factor-1a (HIF-1a) (NM_001530, a pool of four independent siRNAs) and non-coding (scrambled) pool siRNAs were from Dharmacon (Lafayette, CO, USA). The human VEGF-A ELISA kit was purchased from Abnova Corporation (Walnut, CA, USA). For western blotting, primary antibodies were bought from Cell Signaling Technology (Danvers, MA, USA). For flow cytometric analysis, AlexaFluor 488-conjugated antibodies to Ser 473 p-Akt, Thr 37/46 p-4E-BP1, and Ser 235/236 p-S6 ribosomal protein (p-S6RP) were purchased from Cell Signaling Technology. Phycoerythrin (PE)-conjugated anti-CXCR4 antibody was bought from eBioscience (San Diego, CA, USA).
Cell culture and primary samples
The T-ALL cell lines Jurkat, MOLT-4, CEM-S and CEM-R (CEM VBL100, drug-resistant cells overexpressing P-gp 22 ) were grown in RPMI 1640, supplemented with 10% fetal bovine serum. Patient samples or peripheral blood CD4 þ T-lymphocytes from healthy donors was obtained with informed consent according to institutional guidelines and isolated using Ficoll-Paque (Amersham Biosciences, Little Chalfont, UK) for patient lymphoblasts or magnetic labeling (Miltenyi Biotec, Bergisch Gladbach, Germany) for CD4 þ T-lymphocytes. CD4 þ T-lymphocytes (10 5 /well) were cultured in RPMI 1640 media containing 10% fetal bovine serum and stimulated for 48 h with a mixture of 10 mg/ml PHA-M and 50 ng/ml human recombinant interleukin-2 (IL-2) to induce proliferation. Thereafter, 1 mCi (0.037 MBq) [ 3 H]-thymidine was added, and after 16 h the cells were harvested onto filter mats with a Skatron harvester. Filters were counted with a b counter system.
Cell viability analysis
MTT (3-(4,5-Dimethylthythiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assays were performed to assess the sensitivity of cells to drugs, as previously described. 17 
Cell-cycle analysis
Flow-cytometric analysis was performed using a propidium iodide (PI)/RNase A staining according to standard procedures, as described previously. 17 Samples were analyzed by an EPICS XL flow cytometer (Beckman Coulter, Miami, FL, USA) with the appropriate software (System II, Beckman Coulter). At least 15 000 events per sample were acquired.
Transmission electron microscopy analysis
This was carried out according to standard techniques, as described previously. 18 
Fluorescent-labeled inhibitor of caspase assay
This was carried out as detailed elsewhere. 23 
Western blot analysis
This was carried out by standard methods, as previously reported. 17 Analysis with an antibody to b-actin demonstrated equal protein loading.
Polysome analysis, [
3 H]-leucine incorporation and 7 methyl-GTP cap affinity assay These were carried out as reported elsewhere. 24 Cell pellets were lysed in hypotonic buffer (50 mM Tris/HCl, pH 7.5, 7 mM MgCl 2 , 100 mM KCl, 2 mM DTT, 1% NP-40, 500 IU/ml RNAsin) and clarified by centrifugation (13 000 g, 2 min, 4 1C). Supernatants were loaded onto 10 to 50% sucrose density gradients in 20 mM HEPES/KOH (pH 7.5), 100 mM KCl, 2 mM MgCl 2 , for polysome analysis. The polysome profile was generated by measurement of optical density at 254 nm.
T-ALL cell lines were pulse-labeled for 4 h with [ 3 H]-leucine at 2 mCi/ml (0.074 MBq/ml) in leucine-free medium. The amount of radioactivity incorporated into proteins was determined by trichloroacetic acid precipitation.
For 7 methyl-GTP cap affinity assay, 5 Â 10 6 cells were lysed in 600 ml of solubilization buffer (20 mM (HEPES/KOH, pH 7.6, 200 mM KCl, 0.5 EDTA, 20 mM KF, 1 mM K 4 P 2 O 7 , 10% glycerol, 1% NP40, protease inhibitors and 50 mg/ml RNAse-A). Lysates were clarified by centrifugation (13 000 g, 20 min, 4 1C), and supernatants were incubated (2 h, 4 1C) with 7 methyl-GTPSepharose beads in 400-ml binding buffer (50 mM Tris/HCl, pH 7.5, 300 mM KCl, 1 mM EDTA, 20 mM KF, 1 mM K 4 P 2 O 7 , 1 mM DTT and protease inhibitors). Beads were then washed three times in binding buffer and boiled in sample buffer. Protein levels were analyzed by western blot.
Quantitative real time-PCR
This was performed essentially as reported elsewhere. 22 Probes were obtained from Applied Biosystems (Foster City, CA, USA). Primers used were: for CXCR4 sense primer 5 0 -TTCTACCCAAT GACTTGTG-3 0 , antisense primer 5 0 -ATGTAGTAAGGCAGCC AACA-3 0 ; for VEGF-A sense primer 5 0 -GCAGAATCATCACGAA GTGG-3 0 , antisense primer 5 0 -GCATGGTGATGTTGGACTCC-3 0 . The housekeeper gene used was human glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
siRNA transfection
This was carried out as previously reported using Amaxa (Cologne, Germany) nucleofection technology.
22,25
Co-culture with mouse MS-5 stromal cells
Jurkat cells (1 Â 10 6 /ml), were seeded on the top of MS-5 mouse stromal cells (at B70% confluence) for 3 h before the addition of mTOR inhibitors, VCR alone or a combination of the inhibitors and VCR. AMD3100 was used at 5 mg/ml. After 48 h of incubation at 37 1C under hypoxic conditions (1% O 2 ), cells were harvested with trypsin/EDTA, washed and resuspended in binding buffer containing Annexin V-fluorescein isothiocyanate (FITC). Cells were counterstained with a PE-conjugated anti-CD45 antibody or with an irrelevant isotypic control antibody and analyzed by flow cytometry after electronic gating on CD45 þ leukemia cells.
18
Combined drug-effect analysis
The combination effect and potential synergy were evaluated from quantitative analysis of dose-effect relationships, as
Active site mTOR inhibitors in T-ALL C Evangelisti et al described previously. 17 For each combination experiment, a CI (combination index) number was calculated using the Biosoft CalcuSyn software (Cambridge, UK).
Flow-cytometric analysis of Ser 473 p-Akt, Thr 37/46 p-4E-BP1 and Ser 235/236 p-S6RP levels in T-ALL patient samples
Lymphoblasts from pediatric patients with T-ALL were fixed in reagent 1 of the Intraprep Kit (Beckman Coulter) and permeabilized with saponin-based reagent 2, as reported elsewhere. Cells were incubated with primary antibodies conjugated to AlexaFluor 488. A rabbit IgG conjugated to AlexaFluor 488 was used as an irrelevant antibody. Cells were analyzed on a FC500 flow cytometer (Beckman Coulter). At least 5000 events per sample were acquired. 18 Flow-cytometric analysis of putative T-ALL LIC Cells were treated with the drugs for 72 h, then stained with the following antibodies: anti-CD34-PE, anti-CD4-PC5 and anti-CD7-PC7 (all from Beckman Coulter). They were washed once and then incubated with Annexin V-FITC, to detect apoptotic cells. Samples were analyzed by a Navios flow cytometer (Beckman Coulter) equipped with Kaluza software.
Statistical evaluation
The data are presented as mean values from three separate experiments±s.d. Data were statistically analyzed by a Dunnet test after one-way analysis of variance (ANOVA) at a level of significance of Po0.05 vs control samples.
Results
Active site mTOR inhibitors have cytotoxic effects on T-ALL cell lines
The effects of the inhibitors were tested against T-ALL cell lines in 24 h MTT assays comparing them with rapamycin and the dual PI3K/mTOR inhibitor, PI-103. PP-242 was the most powerful of the three mTOR active site inhibitors tested. PP-242 was more efficacious than rapamycin and was slightly more powerful than PI-103, even when used at equimolar concentrations, except on CEM-S cells (Figures 1a-e and Supplementary  Table 1 ). In contrast, CD4 þ T-lymphocytes isolated from the peripheral blood of healthy donors and stimulated with PHA-M plus IL-2, were much less sensitive to PP-242 concentrations up to 2 mM as far as their proliferation (assayed by [ 3 H]-thymidine incorporation) was concerned (Figure 1f) . Similar results were obtained with OSI-027 (data not shown). Overall, these findings demonstrated that active site mTOR inhibitors reduced the growth of T-ALL cell lines. Moreover, they also suggested the drugs could have a favorable therapeutic index, as they did not significantly affect proliferation of normal CD4 þ T-lymphocytes.
PP-242 induces cell-cycle arrest, apoptosis and autophagy
Given the fundamental roles mTORC1 and mTORC2 had in regulating cell-cycle progression, survival and autophagy, we determined whether PP-242 could affect these events in T Figure S1B) . Also, fluorescent-labeled inhibitor of caspase assay documented caspase-9 activation (Supplementary Figure S1C) . Induction of autophagy was confirmed by transmission electron microscopy analysis, the golden standard for autophagy studies, which documented the presence of autophagic vacuoles in the cytoplasm of PP-242-treated CEM-R and Jurkat cells (Supplementary Figure S1D) .
PP-242 and OSI-027 affect mTORC1 and mTORC2 signaling in T-ALL cell lines
Western blot analysis demonstrated a dose-dependent decrease in Ser 473 p-Akt (indicative of mTORC2 inhibition), after 24 h of 
Effects of active site mTOR inhibitors on mRNA translation
Polysome analysis was carried out using Jurkat cells treated with rapamycin, PP-242 or PI-103 at an equimolar concentration (500 nM). Polysomes were separated through sucrose density gradients and their profiles were generated by the measurement of absorbance at 254 nm. Both PP-242 and PI-103 caused an inhibition of translation initiation, as documented by the shift from large to small polysomes. In contrast, rapamycin had no effects (Figure 3a) . The impact of both PP-242 and OSI-027 on protein synthesis was further evaluated by [ 3 H]-leucine incorporation into neo-synthesized proteins of Jurkat and CEM-R cells. Both the inhibitors were as powerful as PI-103 in reducing proteins synthesis, whereas rapamycin did not significantly affect it (Figure 3b) . Translation of mRNA is tightly regulated at the initiation level through the assembly of eIF4F complexes. 27 Using Jurkat cells, we compared the effects of rapamycin, PP-242 and OSI-027 on eIF4F assembly by pull-down assays using 7 methyl-GTP-Sepharose beads that mimic the cap structure of mRNA. 28 Although exposure to rapamycin did not change the amount of eIF4G or 4E-BP1 bound to eIF4E, incubation with either PP-242 or OSI-027 increased the Active site mTOR inhibitors in T-ALL C Evangelisti et al 4E-BP1 levels and decreased the amounts of eIF4G bound to eIF4E, indicating a major inhibition of eIF4F complex assembly (Figure 3c ). Western blots using whole-cell lysates showed that these inhibitors did not significantly reduce the total amounts of eIF4G, eIF4E or 4E-BP1 (Figure 3d) .
Moreover, the expression of three proteins known to be regulated at the translation initiation level, MCL-1, Survivin and CDK-2, 29 was markedly reduced in Jurkat cells after 24 h of exposure to either PP-242 or OSI-027, but not to rapamycin (Figure 3e) . Overall, these findings demonstrated that active site mTOR inhibitors are potent 
Active site mTOR inhibitors counteracts CXCR4-dependent VCR resistance induced in Jurkat cells by co-culturing with MS-5 stromal cells
The leukemic microenvironment is thought to be strongly hypoxic. 30 Cell response to hypoxia comprises upregulation of hypoxia-inducible factor-1a (HIF-1a), which is under control of mTORC1. 31 HIF-1a then induces transcription of a number of genes, including VEGF-A, 32 CXCR4, the receptor for CXCL12 chemokine 33 and PIM-1 kinase. 34 Interactions between CXCR4 and CXCL12 strongly contribute to drug resistance of leukemic cells. 35 In preliminary experiments, we found that hypoxia (1% O 2 for 48 h) markedly increased HIF-1a expression in Jurkat cells, which could be counteracted by either PP-242 or OSI-027 (Figure 4a ). We then investigated whether hypoxia had any impact on VEGF-A and CXCR4 levels. Quantitative real-time-PCR documented a significant increase in VEGF-A and CXCR4 mRNA levels in Jurkat cells cultured under hypoxic conditions for 48 h. The increase was almost completely counteracted by incubation with either PP-242 or OSI-027, or if cells had been treated with siRNA to HIF-1a, but not scrambled siRNA (Figure 4b) . ELISA assay documented an increase in VEGF-A in Jurkat cell culture supernatant under hypoxic conditions. The increase was blunted by PP-242, OSI-027 or siRNA to HIF-1a. Flow-cytometric analysis demonstrated an increase in membrane-bound CXCR4 after culturing Jurkat cells for 48 h at 1% O 2 . The increase was minimal, if cells were treated with PP-242 Active site mTOR inhibitors in T-ALL C Evangelisti et al (Figure 4c ). When Jurkat cells were co-cultured with MS-5 cells under hypoxic conditions, their sensitivity to VCR dramatically decreased when compared with the absence of stromal cells (Figure 4d ). Either PP-242 or OSI-027 partially restored VCR sensitivity of Jurkat cells cultured under hypoxic conditions in the presence of MS-5 cells. Interestingly, the same effect could be achieved by the use of AMD3100, a blocker of the interactions between CXRCR4 and its physiological ligand, CXCL12. 36, 37 However, when no MS-5 cells were present, AMD3100 had no effect (Figure 4d) . Interestingly, also a PIM-1 kinase inhibitor increased Jurkat cell sensitivity to VCR. As expected, hypoxia increased PIM-1 kinase expression levels in Jurkat cells, as documented by western blot analysis (Figure 4e) . The increase was blocked by either PP-242 or OSI-027.
Overall, these findings strongly suggested that mTORC1 could affect the chemosensitivity of T-ALL cells under hypoxic conditions through interactions between CXCR4 and CXCL12 produced by stromal cells and that active site mTOR inhibitors were efficacious in reducing such resistance, most likely also through an increase of PIM-1 kinase expression.
Active site mTOR inhibitors synergize with VCR and ABT-263
It was investigated whether the inhibitors could synergize with VCR, a drug commonly used for treating T-ALL patients, or with ABT-263, a drug which inhibits BCL-2 and is being tested as a therapeutic agent in lymphoid malignancies. 38 T-ALL cell lines were incubated for 24 h with PP-242 alone, either VCR or ABT-263 alone, or the inhibitor plus either VCR or ABT-263 together at a fixed ratio (PP-242:VCR 10:1; PP-242:ABT-263 1:1). MTT assays were then carried out. PP-242 synergized (CIo0.9) with both VCR and ABT-263 (Supplementary Figure  S2) . Similar results were obtained with OSI-027 (data not shown).
T-ALL lymphoblasts are sensitive to active site mTOR inhibitors
To better assess the efficacy of the inhibitors as potential therapeutic agents in T-ALL, we examined eight pediatric T-ALL patient samples isolated from bone marrow or peripheral blood, for their sensitivity to the inhibitors, using flow-cytometric and MTT assays. All of the patients displayed enhanced phosphorylation of Ser 473 p-Akt, Thr 37/46 p-4E-BP1 and Ser 235/236 p-S6RP (data not shown). T-ALL lymphoblast samples were treated with increasing concentrations of either PP-242 or OSI-027, and cell survival was analyzed by MTT assays. A marked reduction of cell viability at 96 h was detected. The IC 50 for patient samples ranged from 0.4 to 2.3 mM for PP-242, whereas for OSI-027 it was 5.5 to 5.8 mM (Figure 5a ). Flowcytometric analysis documented a decrease in the levels of p-Akt, p-4E-BP1 and p-S6RP in mTOR inhibitor-treated samples (Figure 5b) . Overall, these findings demonstrated that the inhibitors displayed cytotoxic activity also against primary cells from T-ALL patients with upregulated PI3K/Akt/mTORC1/mTORC2 signaling.
Active site mTOR inhibitors induce apoptosis in the CD34
þ /CD7 À /CD4 À subset of patient lymphoblasts
Finally, we investigated whether PP-242, OSI-027 or AZD-8055 could induce apoptosis in a T-ALL patient lymphoblast subpopulation (CD34 þ /CD7 À /CD4 À ), which is enriched in putative LIC, 20 using quadruple staining and flow-cytometric analysis. After electronic gating on the CD7 À /CD4 À lymphoblast subset, cells were analyzed for CD34 expression and positivity to Annexin V staining. Depending on the patient, this sub-population comprised 1-2.5% of total lymphoblasts (Figure 6a) . After 72 h of treatment, the drugs markedly induced apoptosis in the CD34 þ /CD7 À /CD4 À sub-population (Figure 6a ). Intriguingly, rapamycin was much less efficacious in this respect. Moreover, PP-242 sensitized this lymphoblast subset to dexamethasone (Figure 6b ), whereas rapamycin was ineffective.
Discussion
Despite the considerable improvements in our knowledge of T-ALL biology in recent years, the treatment of this disease remains a challenge for clinicians. Major efforts have been made to develop new compounds targeting signaling pathways implicated in T-ALL cell proliferation and survival. mTORC1 and mTORC2 represent promising therapeutic targets in a number of cancers as their activities are frequently deregulated in tumor cells. Constitutive activation of mTORC1/2 is a common event in T-ALL, which emphasizes the potential of using mTOR inhibitors as therapeutic agents in this disorder.
First generation mTOR inhibitors of the rapamycin/rapalog family are highly specific mTORC1 allosteric inhibitors. However, in preclinical models of T-ALL the efficacy of rapamycin seems weak, at least in monotherapy settings. 17 One possible strategy to enhance their effectiveness consists on dual inhibition of both the PI3K and mTOR signaling pathways. Indeed, although the constitutive activation events for PI3K and mTORC1 could be independent, the PI3K and mTOR signaling networks are closely related and are subject to complex crosstalk and feedback interactions. In this regard, both PI3K and mTORC2 regulate the full activity of the oncogenic kinase Akt via phosphorylation of Thr 308 and Ser 473, respectively. Indeed, we have documented that dual PI3K/mTOR inhibitors are more efficacious than rapamycin in preclinical T-ALL settings. 17, 18 However, these drugs, by inhibiting PI3K, could also result in more toxic side effects than rapamycin/rapalogs. 39 At present, the new frontier of mTOR inhibition is represented by the use of active site mTOR inhibitors, which target both mTORC1 and mTORC2, without affecting PI3K activity. 9 Accordingly, in our current study we tested the anti-leukemic activity of three compounds that directly target the mTOR catalytic domain. Two of these compounds (PP-242 and OSI-027) have already been tested in other hematological cancers, including Philadelphia þ acute leukemias 39, 40 and multiple myeloma, 41 and promising preclinical data were reported. Interestingly in T-ALL, PP-242 and OSI-027 demonstrated a marked anti-leukemic effects in vitro against both cell lines and patients lymphoblasts. Furthermore, these effects were highly specific to leukemic cells as PP-242 and OSI-027 only slightly affected the proliferation of CD4 þ T-lymphocytes from healthy donors. As expected, the drugs strongly inhibited both mTORC1 and mTORC2 signaling, as evidenced by the decrease of p-p70S6K, and Ser 473 p-Akt, respectively. PP-242 also dephosphorylated Thr 308 p-Akt. This is in agreement with others. 26 However, Thr 308 p-Akt dephosphorylation by PP-242 probably reflects the fact that phosphorylation of this residue requires that Ser 473 p-Akt be phosphorylated. 26, 42 The critical mechanisms underlying PP-242 and OSI-027 function, however, may also result from the inhibition of protein translation. It has been recently emphasized that the weak antileukemic activity of the rapalogs was mainly due to the sustained high level of 4E-BP1 phosphorylation in AML cells treated with these compounds. 28 Conversely, we show herein that in contrast to rapamycin, 17, 18 both PP-242 and OSI-027 strongly blocked mTORC1 catalytic activity. This resulted in the inhibition of Thr 37/46 4E-BP1 phosphorylation residues, which have been reported to be direct substrates for mTOR catalytic activity. 43 Indeed, phosphorylation of the translation repressor 4E-BP1 is the limiting step for the assembly of the translation initiating complexes. As a consequence of 4E-BP1 dephosphorylation, PP-242 markedly inhibited the assembly of eIF4F-initiating complexes and reduced the recruitment of mRNA molecules to polysomes. This resulted in an inhibition of protein synthesis and a decreased expression of oncogenic proteins regulated at the translation initiation level.
PP-242 and OSI-027 were able to counteract the protective function against VCR exerted by MS-5 murine stromal cells (which mimic the bone marrow microenvironment) in a co-culture system with Jurkat cells, under hypoxic conditions, which caused a marked upregulation of HIF-1a and CXCR4. 
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The use of AMD3100, a blocker of the CXCR4/CXCL12 interactions, allowed us to hypothesize that co-culturing could result in further enhancing of mTORC1/mTORC2 signaling and drug-resistance in Jurkat cells. An important protein having a role in hypoxia-induced drug-resistance could be PIM-1 kinase, which is known to be induced by HIF-1a, 34 as demonstrated by the use of a selective PIM-1 kinase inhibitor. 44 Nevertheless, the efficacy of the combined treatment (active site mTOR inhibitors plus VCR) in the presence of stromal cells was inferior to that detected in suspension cultures. This probably reflects activation of additional survival pathways by stromal cells. Indeed, our preliminary data indicate that an inhibitor of MEK/ERK signaling further potentiated the cytotoxic effect of the combined treatment, in agreement with the observation that CXCR4/CXCL12 signaling also controls the MEK/ERK cascade. 45 The difficulty in eradicating tumors might result from the conventional treatments targeting the bulk of the tumor cells, but not the LIC. 46 Therefore, strategies that eliminate these cells could have significant clinical implications. All of the active site mTOR inhibitors we tested, induced apoptosis in a T-ALL lymphoblast sub-population (CD34 þ /CD7 À /CD4 À ), which has been reported to be enriched in LIC in pediatric patients. Intriguingly, rapamycin was not as affective in this respect as the active site mTOR catalytic inhibitors. Moreover, PP-242 increased dexamethasone sensitivity in this lymphoblast subset. This could be related to the fact that PP-242 inhibits Akt phosphorylation, as recent findings have highlighted that in T-ALL cells with constitutive Akt activation, there is an Akt dependent-phosphrylation of the glucocorticoid receptor, NR3C1, on Ser 134. 47 This resulted in a marked decrease in NR3C1 stability, a retention of NR3C1 in the cytosol in the presence of dexamethasone and an impaired glucocorticoid receptor auto-upregulation. Pharmacological inhibition of Akt could effectively reverse glucocorticoid resistance in T-ALL primary human samples and cell lines.
Overall, our present findings firmly establish that active site mTOR inhibitors fulfil the biological criteria for further clinical testing in T-ALL. Indeed, they inhibit mTORC1 and mTORC2 signaling pathways, leading to cytotoxicity in T-ALL cells. Moreover, from the perspective of clinical development, PP-242 and OSI-027 barely impacted on the proliferation of T-lymphocytes from healthy donors, strongly indicative of a favorable therapeutic index in vivo. Clinical trials with either OSI-027 or AZD-8055 are now in progress for advanced solid tumors, including lymphomas (http://www.ClinicalTrials.gov NCT00698243 and NCT00999882). We have provided here a strong rationale for undertaking clinical trials of these drugs also in T-ALL patients in the very near future.
